GlobalData, the industry analysis specialist’s new report, “Crohn’s Disease -Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global Crohn’s disease therapeutics market. The report identifies the key trends shaping and driving the global Crohn’s disease therapeutics market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Crohn’s disease therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.
GlobalData has estimated the global Crohn’s disease therapeutics market to be valued at $2.8 billion in 2009. It is expected to grow to $4.7 billion with a Compound Annual Growth Rate (CAGR) of 6.6% by 2017. This growth is primarily attributed to the increased competition among the existing products and also the strong pipeline with more emerging therapies. The growth will be further supported by the increased uptake of biologics. The growth is attributed to the launches of the biologics which include Humira (Adalimumab), Cimzia (certolizumab pegol) and Tysabri (natalizumab).
The report provides information on the key drivers and challenges of the global crohn’s disease therapeutics market. Its scope includes:
- Annualized global Crohn’s disease market revenues data from 2001 to 2009, forecast forward for 7 years to 2017.
- Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes TNF-alpha inhibitors, stem cell therapy, CCR9 antagonist ,integrin alpha (4) antagonist ,hormone therapy, COX-1 Inhibitor, JAK inhibitors, cytokine production inhibitors, opioid antagonists, NPY Y4 selective agonists, peptidase inhibitors, monoclonal antibodies, selective ROCK I/II inhibitors, permeability inhibitors, TL-1 inhibitors, angiotensin converting enzyme 2 inhibitors, GLP-2 agonist.
- Analysis of the current and future market competition in the global Crohn’s disease market. Key market players covered are Ocera Therapeutics, ChemoCentryx, Osiris, Giaconda Limited, Takeda Pharmaceuticals, Centocor, PanGenetics B.V, Enzo Biochem, Inc., Txcell SA, Pfizer Inc., Celgene Corporation, 7TM Pharma A/S, Teva Pharmaceutical Industries Limited and Amgen.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Crohn’s disease
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Crohn’s disease therapeutics market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Crohn’s disease therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Crohn’s disease therapeutics market landscape? - Identify, understand and capitalize.
Table of Content
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Crohns Disease Therapeutics Market: Introduction 6
2.1 GlobalData Pipeline Report Guidance 6
3 Crohns Disease Therapeutics Market: Market Characterization 7
3.1 Overview 7
3.2 Crohns Disease Therapeutics Market Size 7
3.3 Crohns Disease Therapeutics Market Forecast and CAGR 8
3.4 Drivers and Barriers for the Crohns Disease Therapeutics Market 9
3.4.1 Drivers for the Crohns Disease Therapeutics Market 9
3.4.2 Barriers for the Crohns Disease Market 9
3.5 Opportunity and Unmet Need 10
3.6 Key Takeaway 11
4 Crohns Disease Therapeutics Market: Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in the Crohns Disease Therapeutics Market 13
4.3.1 Entocort EC (budenoside) 13
4.3.2 Humira (adalimumab) 14
4.3.3 Tysabri (natalizumab) 15
4.3.4 Remicade (infliximab) 16
4.3.5 Cimzia (cetrolizumab pegol) 17
4.4 Key Takeaway 19
5 Crohns Disease Therapeutics Market: Pipeline Assessment 20
5.1 Overview 20
5.2 Strategic Pipeline Assessment 20
5.2.1 Technology Trends Analytic Framework 20
5.3 Crohns Disease Therapeutics Promising Drugs under Clinical Development 22
5.4 Molecule Profile for Promising Drugs under Clinical Development 23
5.4.1 Myoconda 23
5.4.2 Traficet-EN (CCX282) 23
5.4.3 MLN0002 (vedolizumab) 24
5.4.4 Prochymal 25
5.4.5 Stelara 25
5.5 Crohns Disease Therapeutics Market Clinical Pipeline by Mechanism of Action 26
5.6 Crohns Disease Therapeutics Pipeline Pipeline by Clinical Phases of Development 27
5.6.1 Crohns Disease Therapeutics Phase III Clinical Pipeline 27
5.6.2 Crohns Disease Therapeutics Phase II Clinical Pipeline 28
5.6.3 Crohns Disease Therapeutics Phase I Clinical Pipeline 29
5.6.4 Crohns Disease Therapeutics Preclinical Pipeline 29
5.6.5 Crohns Disease Therapeutics Discovery Pipeline 29
5.7 Key Takeaway 30
6 Crohns Disease Therapeutics Market: Implications for Future Market Competition 31
7 Crohns Disease Market: Future Players in the Crohns Disease Market 33
7.1 Introduction 33
7.2 ChemoCentryx Inc. 34
7.2.1 Overview 34
7.2.2 Autoimmune and Gastrointestinal Disease Portfolio 34
7.3 Osiris 34
7.3.1 Overview 34
7.3.2 Autoimmune and Gastrointestinal Disease Portfolio 34
7.4 Ocera Therapeutics, Inc. 35
7.4.1 Overview 35
7.4.2 Autoimmune and Gastrointestinal Disease Portfolio 36
7.5 Centocor Ortho Biotech Inc 36
8 Crohns Disease Therapeutics Market: Appendix 37
8.1 Market Definitions 37
8.2 Abbreviations 37
8.3 Research Methodology 38
8.3.1 Coverage 38
8.3.2 Secondary Research 38
8.3.3 Forecasting 39
8.3.4 Primary Research 42
8.3.5 Expert Panel Validation 42
8.4 Contact Us 42
8.5 Disclaimer 42
8.6 Sources 43
List of Table
Table 1: Crohns Disease Therapeutics Market, Global, Revenues ($m), 20012009 7
Table 2: Crohns Disease Therapeutics Market, Global, Market Forecast ($m), 20092017 8
Table 3: Major Marketed Products Comparison in the Crohns Disease Therapeutics Market, 2010 18
Table 4: Crohns Disease Therapeutics Most Promising Drugs Under Clinical Development, 2010 22
Table 5: Crohns Disease Therapeutics Market, Phase III Clinical Pipeline, 2010 27
Table 6: Crohns Disease Therapeutics Market, Phase II Clinical Pipeline, 2010 28
Table 7: Crohns Disease Therapeutics Market, Phase I Clinical Pipeline, 2010 29
Table 8: Crohns Disease Therapeutics Market, Preclinical Pipeline, 2010 29
Table 9: Crohns Disease Therapeutics Market, Discovery Pipeline, 2010 29
Table 10: ChemoCentryx Inc., Autoimmune and Gastrointestinal Disease Pipeline Products, 2010 34
Table 11: Osiris Inc, Autoimmune and Gastrointestinal Disease Pipeline Products, 2010 34
Table 12: Ocera Therapeutics, Inc, Autoimmune and Gastrointestinal Disease Pipeline Products, 2010 36
List of Chart
Figure 1: Crohns Disease Therapeutics Market, Global, Revenues ($m), 20012009 7
Figure 2: Crohns Disease Therapeutics Market, Global, Market Forecast ($m), 20092017 8
Figure 3: Opportunity and Unmet Need in the Crohns Disease Therapeutics Market,2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Crohns Disease,2010 12
Figure 5: Technology Trends Analytic Framework of the Crohns Disease Theraputics Pipeline, 2010 20
Figure 6: Technology Trends Analytic Framework of the Crohns Disease Therapeutics Pipeline Description, 2010 21
Figure 7: Crohns Disease Therapeutics Market, Clinical Pipeline by Mechanism of Action (%),2010 26
Figure 8: Crohns Disease Therapeutics Pipeline by Phase of Clinical Development, 2010 27
Figure 9: Implications for Future Market Competition in the Crohns Disease Therapeutics Market, 2010 31
Figure 10: Crohns Disease Therapeutics Market, Clinical Pipeline by Company, 2010 33
Figure 11: GlobalData Market Forecasting Model 41
Make an enquiry before buying this Report
Please fill the enquiry form below.